<DOC>
	<DOCNO>NCT00008281</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know regimen chemotherapy effective metastatic colorectal cancer . PURPOSE : Phase III trial compare effectiveness three chemotherapy regimen treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Comparison Three Chemotherapy Regimens Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival patient metastatic colorectal carcinoma treat fluorouracil leucovorin calcium v without oxaliplatin v oxaliplatin alone . II . Compare response rate , time tumor-related symptomatic worsening , time disease progression , onset duration complete partial response , duration disease stabilization patient treat regimen . III . Determine safety profile regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord Karnofsky performance status ( 50-60 % vs 70-100 % ) , number metastatic organ ( 1 vs 2 ) , LDH value ( 1.5 time upper limit normal ( ULN ) vs great 1.5 time ULN ) . Patients randomize one three treatment arm . Arm I : Patients receive leucovorin calcium IV 2 hour follow fluorouracil IV continuously 22 hour day 1 2 . Arm II : Patients receive oxaliplatin IV 2 hour day 1 . Arm III : Patients receive oxaliplatin IV concurrently leucovorin calcium IV 2 hour follow fluorouracil IV continuously 22 hour day 1 . Leucovorin calcium fluorouracil administer alone day 2 schedule day 1 . Treatment repeat every 2 week 1 year absence disease progression unacceptable toxicity . Patients follow 30 day , every 2 week 3 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 786 patient ( 262 per arm ) accrue study within 12 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic adenocarcinoma colon rectum amenable potentially curative therapy ( e.g. , inoperable metastatic disease ) At least 1 unidimensionally measurable lesion least 20 mm diameter conventional CT MRI scan least 10 mm diameter spiral CT scan Progressive disease CT MRI scan 6 month last dose prior firstline irinotecan , fluorouracil , leucovorin calcium ( Saltz regimen ) metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN ( great 5 time ULN liver metastasis present ) Alkaline phosphatase great 2 time ULN ( great 3 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled high blood pressure No unstable angina , symptomatic congestive heart failure , serious cardiac arrhythmia No New York Heart Association class III IV heart disease No history cardiac toxicity prior fluorouracil leucovorin calcium No myocardial infarction within past 6 month Pulmonary : No interstitial pneumonia extensive symptomatic fibrosis lung Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No known dihydropyrimidine dehydrogenase deficiency No allergy platinumcontaining drug No history intolerance study antiemetic ( e.g. , 5HT3 antagonist ) No known peripheral neuropathy ( absence deep tendon reflex sole deficiency allow ) No uncontrolled diabetes No active infection No active malignancy originate primary site colon rectum PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics One 1 prior chemotherapy regimen metastatic disease consist firstline irinotecan , fluorouracil , leucovorin calcium ( Saltz regimen ) Prior adjuvant fluorouracil leucovorin calcium allow At least 3 week since prior chemotherapy metastatic disease recover No prior adjuvant irinotecan No prior oxaliplatin Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy study lesion unless evidence progressive disease within radiotherapy port At least 3 week since prior radiotherapy Surgery : See Disease Characteristics At least 4 week since prior major surgery recover Prior surgical resection primary tumor metastasis allow Other : At least 30 day since prior investigational drug No concurrent investigational agent No concurrent anticancer therapy No concurrent participation investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>